Aflibercept, ranibizumab, and bevacizumab for macular neovascularization secondary to age-related macular degeneration: a retrospective OCT-angiography study

Abstract Background Intravitreal aflibercept, ranibizumab, and bevacizumab represent the three most widely used anti-VEGF agents for the treatment of neovascular age-related macular degeneration (AMD). The objective of this study is to compare the loading phase effects of these three agents on the m...

Full description

Bibliographic Details

Published in:	International Journal of Retina and Vitreous
Main Authors:	Marco Lombardo, Carlo Maccauro, Michele D’Ambrosio, Massimo Grossi, Filippo Missiroli, Massimo Cesareo, Federico Ricci
Format:	Article
Language:	English
Published:	BMC 2025-10-01
Subjects:	Age-related macular degeneration AMD Macular neovascularization MNV Anti-VEGF Aflibercept
Online Access:	https://doi.org/10.1186/s40942-025-00740-y